The application relates to pharmaceutical formulation and a process for its preparation. The pharmaceutical formulation comprises cinnamic acid and at least one excipient. The pharmaceutical formulation of the present disclosure has improved patient compliance, and reduced adverse effects. The pharmaceutical formulation of the present disclosure can be used in the treatment of cyclophosphamide induced neutropenia. …
Category: Pharmaceutical
Pharmaceutical Compositions Comprising Picroside
The patent discloses a pharmaceutical composition comprising picroside isolated from Picrorrhize kurroa. The composition contains Picroside I as an active ingredient for treating drug-induced immunopathy such as neutropenia. Methods of isolating Picroside I and Picroside II, and preparing the compositions have also been disclosed herein. The said composition of Picroside I can be a solid oral …
Cisplatin Nanoparticle Composition (Oral Administration)
ID: VR-01 Cisplatin is a chemotherapy drug used to treat a variety of cancers, including testicular, lung, bladder, cervical, and ovarian cancers. It’s an alkylating agent that contains platinum, which damages DNA and stops cells from dividing. Cisplatin Market size was valued at USD 14.2 Billion in 2023 and is projected to reach USD 25.6 Billion by 2031, …
Migraine Formulation
ID: TP-01 Migraine is a neurological disorder that causes headaches that are often severe and throbbing. Migraines can also cause nausea, vomiting, and sensitivity to light and sound. Migraines can last for hours or days. The global migraine drugs market size was estimated at USD 5.64 billion in 2023 and is projected to grow at a CAGR of …